Literature DB >> 20300881

Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines.

Florian Krammer1, Theresa Schinko, Dieter Palmberger, Christopher Tauer, Paul Messner, Reingard Grabherr.   

Abstract

Virus-like particles (VLPs) consisting of the influenza A virus proteins haemagglutinin (HA) and matrix protein (M1) represent a new alternative approach for vaccine design against influenza virus. Influenza VLPs can be fast and easily produced in sufficient amounts in insect cells using the baculovirus expression system. Up to now, influenza VLPs have been produced in the Spodoptera frugiperda cell line Sf9. We compared VLP production in terms of yield and quality in two insect cell lines, namely Sf9 and the Trichoplusia ni cell line BTI-TN5B1-4 (High Five). Additionally we compared VLP production with three different HAs and two different M1s from influenza H1 and H3 strains including one swine-origin pandemic H1N1 strain. Comparison of the two cell lines showed dramatic differences in baculovirus background as well as in yield and particle density. Taken together, we consider the establishment of the BTI-TN5B1-4 cell line advantageous as production cell line for influenza VLPs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20300881      PMCID: PMC4388404          DOI: 10.1007/s12033-010-9268-3

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  35 in total

Review 1.  Baculoviral vectors for gene delivery: a review.

Authors:  Yu-Chen Hu
Journal:  Curr Gene Ther       Date:  2008-02       Impact factor: 4.391

2.  Occlusion-derived baculovirus: interaction with human cells and evaluation of the envelope protein P74 as a surface display platform.

Authors:  Anna R Mäkelä; Jenni E Tuusa; Loy E Volkman; Christian Oker-Blom
Journal:  J Biotechnol       Date:  2008-04-07       Impact factor: 3.307

Review 3.  Recombinant baculoviruses as expression vectors for insect and mammalian cells.

Authors:  T A Kost; J P Condreay
Journal:  Curr Opin Biotechnol       Date:  1999-10       Impact factor: 9.740

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Authors:  Rick A Bright; Donald M Carter; Shannon Daniluk; Franklin R Toapanta; Attiya Ahmad; Victor Gavrilov; Mike Massare; Peter Pushko; Nutan Mytle; Thomas Rowe; Gale Smith; Ted M Ross
Journal:  Vaccine       Date:  2007-02-15       Impact factor: 3.641

6.  H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

Authors:  Kutubuddin Mahmood; Rick A Bright; Nutan Mytle; Donald M Carter; Corey J Crevar; Jenna E Achenbach; Penny M Heaton; Terrence M Tumpey; Ted M Ross
Journal:  Vaccine       Date:  2008-08-14       Impact factor: 3.641

7.  Influence of promoter choice and trichostatin A treatment on expression of baculovirus delivered genes in mammalian cells.

Authors:  Alexandra Spenger; Wolfgang Ernst; J Patrick Condreay; Thomas A Kost; Reingard Grabherr
Journal:  Protein Expr Purif       Date:  2004-11       Impact factor: 1.650

Review 8.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

9.  Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.

Authors:  Lucy A Perrone; Attiya Ahmad; Vic Veguilla; Xiuhua Lu; Gale Smith; Jacqueline M Katz; Peter Pushko; Terrence M Tumpey
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

10.  Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.

Authors:  Florian Krammer; Sabine Nakowitsch; Paul Messner; Dieter Palmberger; Boris Ferko; Reingard Grabherr
Journal:  Biotechnol J       Date:  2010-01       Impact factor: 4.677

View more
  50 in total

Review 1.  Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships.

Authors:  John F Cipollo; Lisa M Parsons
Journal:  Mass Spectrom Rev       Date:  2020-04-29       Impact factor: 10.946

2.  Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.

Authors:  Guha Asthagiri Arunkumar; Andriani Ioannou; Teddy John Wohlbold; Philip Meade; Sadaf Aslam; Fatima Amanat; Juan Ayllon; Adolfo García-Sastre; Florian Krammer
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

3.  Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.

Authors:  Teddy John Wohlbold; Veronika Chromikova; Gene S Tan; Philip Meade; Fatima Amanat; Phillip Comella; Ariana Hirsh; Florian Krammer
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

4.  Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.

Authors:  James Duehr; Teddy John Wohlbold; Lisa Oestereich; Veronika Chromikova; Fatima Amanat; Madhusudan Rajendran; Sergio Gomez-Medina; Ignacio Mena; Benjamin R tenOever; Adolfo García-Sastre; Christopher F Basler; Cesar Munoz-Fontela; Florian Krammer
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

5.  Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Irina Margine; Gene S Tan; Ariana Hirsh; Florian Krammer
Journal:  Vaccine       Date:  2015-05-28       Impact factor: 3.641

6.  Broad Spectrum Inhibitor of Influenza A and B Viruses Targeting the Viral Nucleoprotein.

Authors:  Kris M White; Pablo Abreu; Hui Wang; Paul D De Jesus; Balaji Manicassamy; Adolfo García-Sastre; Sumit K Chanda; Robert J DeVita; Megan L Shaw
Journal:  ACS Infect Dis       Date:  2018-01-04       Impact factor: 5.084

7.  A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells.

Authors:  Hideaki Mabashi-Asazuma; Chu-Wei Kuo; Kay-Hooi Khoo; Donald L Jarvis
Journal:  Glycobiology       Date:  2013-12-20       Impact factor: 4.313

8.  An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

Authors:  Florian Krammer; Asne Jul-Larsen; Irina Margine; Ariana Hirsh; Haakon Sjursen; Maria Zambon; Rebecca J Cox
Journal:  Clin Vaccine Immunol       Date:  2014-06-18

9.  Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.

Authors:  Raffael Nachbagauer; David Shore; Hua Yang; Scott K Johnson; Jon D Gabbard; S Mark Tompkins; Jens Wrammert; Patrick C Wilson; James Stevens; Rafi Ahmed; Florian Krammer; Ali H Ellebedy
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

10.  Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system.

Authors:  Irina Margine; Peter Palese; Florian Krammer
Journal:  J Vis Exp       Date:  2013-11-06       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.